A phase 2 clinical trial led by the University of Pittsburgh, UPMC Hillman Cancer Center, and the National Cancer Institute showed promising results in treating stage 3 cutaneous melanoma with a combination of the experimental drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab. The treatment led to tumor control in 55% of patients and produced high response rates and survival rates. Further research revealed that the combination therapy enriched specific immune cells in responding patients, suggesting a unique mechanism of action. The study also identified potential pharmacodynamic markers and highlighted the complexity of the gut microbiome’s effects on cancer immunotherapy.
Source link
Combination therapy shows promising results in treating stage 3 melanoma
